UBS Group’s Entera Bio Ltd. Warrant ENTXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,100
| Closed | -$81 | – | 10227 |
|
|
2023
Q1 | $81 | Buy |
3,100
+1,854
| +149% | +$80 | ﹤0.01% | 9273 |
|
|
2022
Q4 | $37 | Buy |
+1,246
| New | +$62 | ﹤0.01% | 10509 |
|
|
2022
Q2 | – | Sell |
-129
| Closed | – | – | 11366 |
|
|
2022
Q1 | $0 | Sell |
129
-1,284
| -91% | -$373 | ﹤0.01% | 11259 |
|
|
2021
Q4 | $0 | Buy |
1,413
+235
| +20% | +$105 | ﹤0.01% | 11002 |
|
|
2021
Q3 | $1K | Sell |
1,178
-347
| -23% | -$278 | ﹤0.01% | 9337 |
|
|
2021
Q2 | $2K | Buy |
+1,525
| New | +$745 | ﹤0.01% | 9034 |
|
|
2021
Q1 | – | Sell |
-2,737
| Closed | – | – | 9668 |
|
|
2020
Q4 | $0 | Sell |
2,737
-600
| -18% | -$75 | ﹤0.01% | 8927 |
|
|
2020
Q3 | $0 | Sell |
3,337
-2,404
| -42% | -$739 | ﹤0.01% | 8578 |
|
|
2020
Q2 | $1K | Buy |
5,741
+953
| +20% | +$383 | ﹤0.01% | 7836 |
|
|
2020
Q1 | $1K | Buy |
4,788
+294
| +7% | +$99 | ﹤0.01% | 7842 |
|
|
2019
Q4 | $1K | Buy |
4,494
+100
| +2% | +$20 | ﹤0.01% | 8006 |
|
|
2019
Q3 | $0 | Buy |
4,394
+1
| +0% | +$1 | ﹤0.01% | 8366 |
|
|
2019
Q2 | $0 | Hold |
4,393
| – | – | ﹤0.01% | 8261 |
|
|
2019
Q1 | $1K | Buy |
4,393
+130
| +3% | +$118 | ﹤0.01% | 7588 |
|
|
2018
Q4 | $2K | Buy |
4,263
+692
| +19% | +$630 | ﹤0.01% | 7833 |
|
|
2018
Q3 | $3K | Buy |
+3,571
| New | +$3.29K | ﹤0.01% | 7681 |
|
UBS Group's ENTXW Position: Q2 2023 in Review
UBS Group sold out of Entera Bio Ltd. Warrant (ENTXW) in Q2 2023, closing a stake of 3,100 shares — an estimated $81 sold.
UBS Group first reported a position in ENTXW in Q3 2018 and held it in 16 quarters. The position peaked at $3K in Q3 2018. 0 funds tracked by Wall St. Rank hold ENTXW as of Q2 2023.
- UBS Group reported no remaining Entera Bio Ltd. Warrant position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 3,100 Entera Bio Ltd. Warrant shares in Q2 2023, an estimated $81.
- UBS Group first reported a position in Entera Bio Ltd. Warrant in Q3 2018 and held it in 16 quarters.
- UBS Group's Entera Bio Ltd. Warrant position peaked at $3K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Entera Bio Ltd. Warrant as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.